The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 34956436 · doi:10.1155/2021/2074610
What was done
Authors systematically reviewed eight English and Chinese databases (PubMed, Embase, Web of Science, Cochrane Library, CNKI, SinoMed, Wanfang, Chinese VIP) for randomized controlled trials evaluating berberine alone or with standard therapy in type 2 diabetes mellitus. Outcomes assessed across 46 trials included glycemic metrics (HbA1c, fasting plasma glucose [FPG], 2-hour postprandial glucose [2hPG]), insulin resistance and weight (fasting insulin [FINS], HOMA-IR, BMI), lipid profiles (triglycerides [TG], total cholesterol [TC], LDL, HDL), inflammatory markers (CRP, IL-6, TNF-alpha), and renal/safety parameters (serum creatinine, BUN, adverse events).
What was found
Berberine significantly reduced glycemic markers: HbA1c (MD = -0.73; 95% CI [-0.97, -0.51]), FPG (MD = -0.86; 95% CI [-1.10, -0.62]), and 2hPG (MD = -1.26; 95% CI [-1.64, -0.89]). It reduced insulin resistance markers: FINS (MD = -2.05; 95% CI [-2.62, -1.48]), HOMA-IR (MD = -0.71; 95% CI [-1.03, -0.39]), and BMI (MD = -1.07; 95% CI [-1.76, -0.37]). For lipids, TG decreased (MD = -0.5; 95% CI [-0.61, -0.39]), TC and LDL were reduced (abstract reports positive point estimates 0.64 and 0.86 alongside negative 95% CIs of [-0.78, -0.49] and [-1.06, -0.65], respectively), and HDL increased (MD = 0.17; 95% CI [0.09, 0.25]). No numerical values were reported in the abstract for inflammatory markers, renal labs, or adverse event frequencies.
Why it matters
This review synthesizes 46 trials to demonstrate that berberine consistently improves glycemic control, insulin sensitivity, and lipid parameters, supporting its role as an adjunctive metabolic agent in type 2 diabetes.
Limits
The total participant count, trial durations, and specific berberine dosages were not reported in the abstract. Numerical data were omitted for inflammation outcomes and all safety parameters (adverse events, creatinine, BUN). The abstract also contains apparent reporting typos in the sign of the effect estimates for TC and LDL.
Cited by
- supports Berberine mimics the metabolic effects of metformin, and taking 1,500 mg daily divided into three 500 mg doses right before meals blunts postprandial blood glucose spikes.